POLA1

Across TCGA pan-cancer cohorts, POLA1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated POLA1 data layer compared with 25 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher POLA1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated POLA1 expression acts as an unfavorable survival marker, although some lineages such as LSCC and UCEC show a favorable association.

PDAC, LSCC, and HNSC are the cancer types where POLA1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.279	0.746	<.001	50	view →
LSCC	DFS	Quartile	II,III,IV	0.866	0.352	.001	38	view →
HNSC	DFS	Tertile	III,IV	0.626	0.899	.007	32	view →
UCEC	DFS	Median	All	1.000	0.940	.034	10	view →
CCRCC	DFS	Tertile	III,IV	0.687	1.000	.033	9	view →
LUAD	OS	Median	All	0.687	0.940	.033	5	view →
GBM	OS	Median	All	0.805	0.908	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

POLA1–PDAC (OS)

Open the PDAC breakdown →